Patents by Inventor Paivi E. PAJUKANTA

Paivi E. PAJUKANTA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • as a diagnostic and therapeutic target for NAFLD, NASH, metabolic syndrome, and hepatic fibrosis
    Patent number: 11274303
    Abstract: An oligonucleotide that inhibits expression of an OLMALINC nucleic acid molecule, such as a small inhibitory RNA (siRNA) molecule, can be used for inhibiting the expression of OLMALINC in a subject. Methods of assaying for OLMALINC in a tissue sample can be used for detecting a disorder associated with obesity and/or type 2 diabetes in a tissue sample obtained from a subject. A method of ameliorating symptoms associated with obesity and/or type 2 diabetes comprises administering to a subject in need thereof an effective amount of an oligonucleotide of the invention or an antibody or equivalent thereof that specifically binds to and inactivates an OLMALINC nucleic acid molecule. Representative examples of a disorder associated with obesity and/or type 2 diabetes include, but are not limited to, a disorder of appetite, glycemia, body weight, liver steatosis, NASH, NAFLD, or a lipid disorder.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 15, 2022
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF EASTERN FINLAND
    Inventors: Paivi E. Pajukanta, Joseph R. Pisegna, Jihane N. Benhammou, Arthur Ko, Jussi Pihlajamäki
  • OLMALINC AS A DIAGNOSTIC AND THERAPEUTIC TARGET FOR NAFLD, NASH, METABOLIC SYNDROME, AND HEPATIC FIBROSIS
    Publication number: 20200283767
    Abstract: An oligonucleotide that inhibits expression of an OLMALINC nucleic acid molecule, such as a small inhibitory RNA (siRNA) molecule, can be used for inhibiting the expression of OLMALINC in a subject. Methods of assaying for OLMALINC in a tissue sample can be used for detecting a disorder associated with obesity and/or type 2 diabetes in a tissue sample obtained from a subject. A method of ameliorating symptoms associated with obesity and/or type 2 diabetes comprises administering to a subject in need thereof an effective amount of an oligonucleotide of the invention or an antibody or equivalent thereof that specifically binds to and inactivates an OLMALINC nucleic acid molecule. Representative examples of a disorder associated with obesity and/or type 2 diabetes include, but are not limited to, a disorder of appetite, glycemia, body weight, liver steatosis, NASH, NAFLD, or a lipid disorder.
    Type: Application
    Filed: October 5, 2018
    Publication date: September 10, 2020
    Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, UNITED STATES GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSITY OF EASTERN FINLAND
    Inventors: Paivi E. PAJUKANTA, Joseph R. PISEGNA, Jihane N. BENHAMMOU, Arthur KO, Jussi PIHLAJAMÄKI